Day: September 4, 2025

Dubai, Sept. 04, 2025 (GLOBE NEWSWIRE) — The annual general meeting of Vantage Drilling International Ltd. (the “Company“) will be held on 16 October 2025, at 11:00 a.m. Atlantic Time at the law offices of Conyers Dill & Pearman Limited, located at Richmond House, 2nd Floor, 12 Par-la-ville Road, Hamilton HM08, Bermuda. The notice of the annual general meeting is attached, together with the attendance and proxy forms. The notice is also available on the Company’s website https://vantagedrilling.com/. About the CompanyVantage Drilling International Ltd., a Bermuda exempted company, is an offshore drilling contractor. Vantage Drilling’s primary business is to contract drilling units, related equipment and work crews primarily on a dayrate basis to drill oil and natural gas wells globally for major, national...

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 Following Q4 2025 and Q1 2026 Regulatory Submissions CRO Brings Over 28 Years of Drug Development Experience and Proven Phase 3 Oncology Trial Expertise to Support Upcoming Trial GRAND CAYMAN, Cayman Islands, Sept. 04, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has selected a contract research organization (“CRO”) to support its upcoming Phase 2/3 clinical trials for SIL204, the Company’s next-generation siRNA...

Peer-to-peer educational initiative reinforces commitment to capturing U.S. advisor market as part of global expansion strategy SAINT HELIER, Jersey – September 4, 2025 – CoinShares International Limited (Nasdaq Stockholm: CS; USOTCQX: CNSRF), Europe’s largest digital asset investment manager, today announced the launch of “The Advisor Series,” an exclusive educational video content platform that advances the company’s aggressive U.S. market expansion strategy through its strengthened partnership with TMX VettaFi. Strategic Market Positioning The initiative represents a significant milestone in CoinShares’ systematic approach to capturing market leadership in the world’s largest wealth management market. Following the strategic acquisition of Valkyrie in 2021, now CoinShares Valkyrie, CoinShares has...

Progress on carbon goals, expanded community impact, and continued water quality excellenceH2O America 2024 Sustainability ReportCover of H2O America’s 2024 Sustainability Report.SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) — H2O America (Nasdaq: HTO), one of the nation’s largest investor-owned water and wastewater utilities, today announced the release of its 2024 Corporate Sustainability Report. The report highlights the company’s sustainability and community impact achievements across its operations in California, Connecticut, Maine and Texas. “In 2024, we deepened our commitment to sustainability while continuing to deliver high-quality water and exceptional service,” said Andrew F. Walters, CEO of H2O America. “From expanding solar energy generation to launching our Force for Good Foundation, we’re proud...

REYKJAVIK, Iceland, June 4, 2025 – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET). A live webcast of the fireside chat will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/morgan-stanley-23rd-annual-global-healthcare-conference-new-york. After the event, a recording will be available for replay for...

REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET). A live webcast of the fireside chat will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/morgan-stanley-23rd-annual-global-healthcare-conference-new-york. After the event, a recording will be available...

SANTA CLARA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (“Silvaco”) (NASDAQ: SVCO), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced that, following a comprehensive search, it has appointed Chris Zegarelli as Chief Financial Officer, effective September 15, 2025. As a senior member of the executive team, Chris will report directly to CEO Dr. Walden Rhines. “We’re excited to welcome Chris Zegarelli as our new CFO. He brings not only deep financial expertise but also a growth mindset and a track record of scaling companies in fast-moving semiconductor and technology markets,” said Dr. Rhines. “As we continue to innovate and expand globally, Chris will be a key partner in driving our strategy, fueling...

$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the pricing of a public offering of an aggregate of 5,999,999 of the Company’s American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, at a combined public offering price of $1.00 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have...